Last reviewed · How we verify
NCT07332663
Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection
EARLY_PHASE1 trial testing WGb-0301 injection in B Cell Malignancies in 9 participants. Not yet recruiting.
31 December 2027
Quick facts
| Lead sponsor | Sichuan University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 1 January 2026 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2028 |
Drugs / interventions tested
- WGb-0301 injection — full drug profile →
Conditions studied
- B Cell Malignancies — all drugs for B Cell Malignancies →
Sponsor
Sichuan University
Who can join
Adults 18 to 70, any sex, with B Cell Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Malignant hematological tumors mainly derived from adult B cells are mainly acute lymphoblastic leukemia (ALL) and non Hodgkin lymphoma (NHL). Overall, although existing therapies have significantly improved the survival rates of most patients, the treatment of relapsed/refractory patients still faces significant challenges. CD19 is one of the most clinically valuable targets for B-cell malignant hematological tumors. The advent of COVID-19 vaccine has brought LNP mRNA technology into the public's view. After years of development, it not only shines brilliantly in COVID-19 vaccine, but also is widely used in the treatment and exploration of cancer, rare diseases and other fields. The core of LNP mRNA technology targeting CD19 is to encapsulate the mRNA encoding specific proteins in lipid nanoparticles and deliver them to the body through intravenous or intramuscular injection. The experimental drug WGb-0301 injection is a CD19 based messenger RNA (mRNA) therapeutic mRNA drug, formed by loading mRNA onto lipid nanoparticles (LNP). WGb-0301 injection has demonstrated efficient B-cell clearance activity and good safety in non clinical settings, supporting further clinical exploration in B-cell malignancies. It is expected to provide an innovative, safe, and accessible immunotherapy for B-cell malignancies, bringing better clinical benefits to more patients with B-cell malignancies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07332663
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of WGb-0301 injection
Trials testing the same drug.
- NCT07349823 — Exploratory Study on the Treatment of Relapsed and Refractory Immune Related Diseases With WGb-0301 Injection · EARLY_PHASE1 · not yet recruiting
Other recruiting trials for B Cell Malignancies
Currently open trials in the same condition.
- NCT07135466 — A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expres · Phase 1, PHASE2 · recruiting
- NCT06576102 — Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients · active not recruiting
- NCT06375161 — Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients. · EARLY_PHASE1 · recruiting
- NCT05995015 — 4SCAR19U T Cells Targeting B Cell Malignancies · Phase 1 · recruiting
- NCT05436496 — CD19/70 Bi-specific CAR-T Cell Therapy · Phase 1, PHASE2 · recruiting
Other Sichuan University trials
Trials by the same sponsor.
- NCT07501169 — Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lun · Phase 2 · not yet recruiting
- NCT07362732 — Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection · EARLY_PHASE1 · not yet recruiting
- NCT07374250 — Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07258147 — Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases · Phase 2 · not yet recruiting
- NCT07211009 — Patient-Reported Symptom Care Versus Usual Care After Esophageal Cancer Surgery: A Single-Center Phase 3 Randomized Tria · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07332663 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sichuan University
- Last refreshed: 12 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07332663.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing